Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Hemangioblastoma Market Size

ID: MRFR//4943-HCR | 100 Pages | Author: Rahul Gotadki| April 2024

The market for hemangioblastoma is fundamentally impacted by the rate and predominance of this interesting tumor. With an expected rate of 1 out of 100,000 individuals, the market elements are molded by the generally low number of cases, prompting restricted drug improvement and particular treatment choices.
The market is receptive to progressions in analytic advancements. Further developed imaging strategies, for example, magnetic resonance imaging (MRI) and hereditary testing, assume an essential part in early detection and finding. These developments drive interest for indicative instruments and add to a superior comprehension of the infection, impacting market growth.
The market is impacted by the accessible treatment modalities for hemangioblastoma. Careful resection stays an essential choice, yet improvements in designated treatments and radiation treatment are acquiring consideration. The rise of novel medicines can possibly reshape the market scene and give more choices to patients.
The market is delicate to the medical services infrastructure in various locales. Admittance to clinical focuses, talented medical services experts, and high-level therapy offices impacts the general market growth. Differences in medical services infrastructure add to varieties in finding rates and therapy results.
The powerful scene of the hemangioblastoma market is formed by drug organizations putting resources into innovative work. Contest among organizations for novel treatments, licenses, and piece of the pie drives development and can prompt a differentiated scope of treatment choices for patients.
The market is receptive to repayment arrangements and protection inclusion for hemangioblastoma medicines. Sufficient repayment can emphatically impact the reception of new treatments and guarantee more extensive access for patients, while impediments in repayment might present difficulties for market growth.

Hemangioblastoma Market Scenario

The hemangioblastoma market is expected to grow USD 3.87 billion at a CAGR 7.30% during the forecast period (2023–2030).

Hemangioblastoma is a type of brain tumor, it is rare and slow growing disease. Uncontrolled growth occurs in the cell linings of blood vessels and it leads to a tumor. The disease-causing factor is unknown, but it is more likely to affect people with von Hippel-Lindau disease history or it can be sporadically. The growing awareness about cancer, increasing number of tumor surgeries, growing demand for advanced therapies and increasing healthcare expenditure are expected to drive the growth of the market. According to National Center for Biotechnology Information, US National Library of Medicine, 80% cases of hemangioblastoma are sporadic, whereas 20 to 25% develop in the context of Von Hippel–Lindau disease and it accounts for 7 to 10% of total brain tumor cases.

The rising cost of tumor treatment and scarcity of experts may hamper the growth of the market during the assessment period.


The global hemangioblastoma market has been segmented on the basis of tumor site, diagnosis, and treatment.

On the basis of tumor site, the market has been classified as brain tumor, spinal cord tumor, and retinal tumor. The diagnosis segment has been classified as CT scan, MRI scan, and angiogram.

The market, by treatment, has been segmented into surgery, chemotherapy, radiotherapy, corticosteroids, and anticonvulsants. Radiotherapy segment has been classified into Conformal radiotherapy, Intensity-modulated radiotherapy (IMRT), Stereotactic radiotherapy and radiosurgery. Corticosteroid segment has been further divided into hydrocortisone, dexamethasone, methylprednisolone, and prednisolone. anticonvulsants segment has been further divided into carbamazepine, lamotrigine, levetiracetam, phenytoin, and sodium valproate.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The hemangioblastoma market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European hemangioblastoma market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The hemangioblastoma market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The hemangioblastoma market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Global Hemangioblastoma Market Share, by Region, 2017 (%)

Hemangioblastoma Market Share

Source: MRFR Analysis

The Americas are likely to dominate the global hemangioblastoma market owing to the adoption of highly advanced technology, the presence of a well-established healthcare system, rising prevalence of cancer, and increasing healthcare expenditure. According to the National cancer institute, in 2016, 15.5 million cancer cases were found in united states, and it is expected to reach 20.3 million by 2016. Also, the expenditure on cancer care in 2017 was 147.3 billion.

The European market is expected to be the second-largest hemangioblastoma market. The market growth in this region can be attributed to government funding and support of the healthcare sector and increasing cancer cases in the region. According to the European Commission, in 2016, The European nations (EU28), total expenditure of general governments on 'healthcare' amounted to 7.1 % of GDP and it was around USD1000 billion.

Asia-Pacific is expected to be the fastest-growing hemangioblastoma market during the forecast period owing to the increasing prevalence of chronic diseases, government support, rising investments in healthcare and presence of huge population. According to the World Economic Forum, in 2017, more than 55% of deaths occurred due to chronic and non-communicable diseases, which is more than 8 million and out of this one-third, people were below 60years.

The market in the Middle East & Africa is expected to account for the smallest share of the global hemangioblastoma market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Key Players

Some of the key players in the global hemangioblastoma market are Eli Lilly and Company, Bedford Laboratories, Astellas US Holding, Inc., DNAtrix, Inc., Advantagene, Inc., Burzynski Research Institute, Inc., Direct Therapeutics, Inc., Cellectar Biosciences, Inc., and others.

Global Hemangioblastoma Market, by Tumor Site

  • Brain

  • Spinal Cord

  • Retina

Global Hemangioblastoma Market, by Diagnosis

  • CT Scan

  • MRI Scan

  • Angiogram

Global Hemangioblastoma Market, by Treatment

  • Surgery

  • Chemotherapy

  • Radiotherapy

    • Conformal Radiotherapy

    • Intensity Modulated Radiotherapy (IMRT)

    • Stereotactic Radiotherapy

    • Radiosurgery

  • Corticosteroids

    • Hydrocortisone

    • Dexamethasone

    • Methylprednisolone

    • Prednisolone

  • Anticonvulsants

    • Carbamazepine

    • Lamotrigine

    • Levetiracetam

    • Phenytoin

    • Sodium Valproate

Global Hemangioblastoma Market, by Region

  • North America

    • US

    • Canada

  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe

  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific

  • Rest of the World

    • Middle East

    • Africa

    • Latin America

Company Profiles    

  • Eli Lilly and Company

  • Bedford Laboratories

  • Astellas US Holding, Inc.

  • DNAtrix, Inc.

  • Advantagene, Inc

  • Burzynski Research Institute, Inc.

  • Direct Therapeutics, Inc.

  • Cellectar Biosciences, Inc.

  • Others

Intended Audience

  • Healthcare providers

  • Medical device manufacturers

  • Research institutes and academic centers

  • Contract research organizations (CROs)

  • Pharmaceutical companies

  • Government associations

  • Market research and consulting

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.